Fish-Derived Omega-3 Fatty Acids and Prostate Cancer: A Systematic Review.

Background The use of natural health products in prostate cancer (PrCa) is high despite a lack of evidence with respect to safety and efficacy. Fish-derived omega-3 fatty acids possess anti-inflammatory effects and preclinical data suggest a protective effect on PrCa incidence and progression; however, human studies have yielded conflicting results. Methods A search of OVID MEDLINE, Pre-MEDLINE, Embase, and the Allied and Complementary Medicine Database (AMED) was completed for human interventional or observational data assessing the safety and efficacy of fish-derived omega-3 fatty acids in the incidence and progression of PrCa. Results Of 1776 citations screened, 54 publications reporting on 44 studies were included for review and analysis: 4 reports of 3 randomized controlled trials, 1 nonrandomized clinical trial, 20 reports of 14 cohort studies, 26 reports of 23 case-control studies, and 3 case-cohort studies. The interventional studies using fish oil supplements in patients with PrCa showed no impact on prostate-specific antigen levels; however, 2 studies showed a decrease in inflammatory or other cancer markers. A small number of mild adverse events were reported and interactions with other interventions were not assessed. Cohort and case-control studies assessing the relationship between dietary fish intake and the risk of PrCa were equivocal. Cohort studies assessing the risk of PrCa mortality suggested an association between higher intake of fish and decreased risk of prostate cancer-related death. Conclusions Current evidence is insufficient to suggest a relationship between fish-derived omega-3 fatty acid and risk of PrCa. An association between higher omega-3 intake and decreased PrCa mortality may be present but more research is needed. More intervention trials or observational studies with precisely measured exposure are needed to assess the impact of fish oil supplements and dietary fish-derived omega-3 fatty acid intake on safety, PrCa incidence, treatment, and progression.

Integrative cancer therapies. 2016 Jun 29 [Epub ahead of print]

Monique Aucoin, Kieran Cooley, Christopher Knee, Heidi Fritz, Lynda G Balneaves, Rodney Breau, Dean Fergusson, Becky Skidmore, Raimond Wong, Dugald Seely

Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada., Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada., Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada., Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada., University of Toronto, Toronto, Ontario, Canada., Ottawa Hospital General Campus, Ottawa, Ontario, Canada., Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada., McMaster University, Hamilton, Ontario, Canada., Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada Ottawa Hospital Research Institute, Ottawa, Ontario, Canada Ottawa Integrative Cancer Centre, Ottawa, Ontario, Canada .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe